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Recently, an association between two polymorphisms (1181G>C and 245T>G) of the osteoprotegerin (OPG) gene and diabetic Charcot neuroarthropathy was suggested on the basis of studies of a limited number of samples derived from subjects from one geographical region (Italy). The aim of this study was to assess the presence of various osteoprotegerin gene polymorphisms in diabetic  patients with Charcot osteoarthropathy as compared with subjects with diabetic neuropathy but no Charcot foot and healthy controls, all from another geographical region (Poland). DNA was isolated from 54 patients with Charcot osteoarthropathy (the Ch group), 35 subjects with diabetic neuropathy but no Charcot foot (the ND group) and 95 healthy controls (the C group) to evaluate OPG gene polymorphisms and their possible contribution to the development of Charcot neuroarthropathy. Statistically significant differences between ND and C groups were found for 1217C>T, 1181G>C, 950T>C and 245T>G polymorphisms, between Ch and C groups for 1217C>T, 1181G>C and 950T>C polymorphisms, and between ND and Ch groups for 1217C>T and 245T>G polymorphisms. Therefore, we suggest that genetic factors, particularly the OPG gene polymorphisms, may play a role in development of diabetic Charcot neuroarthropathy, indeed. 











Charcot osteoarthropathy, occurring in diabetic patients, is characterized by progressive destruction of bones and joints of the diabetic foot with accompanying osteopenia (1). The incidence of this complication is reported in various population-based studies to be in the range between 0.1% up to nearly 30% (2). The clinical picture of the acute phase of this diabetic complication can mimic several other pathologies, e.g. DVT, cellulitis, gout or simple sprain. Due to the lack of specific markers of Charcot arthropathy, according to some authors, as many as 25% of cases can be missed or the diagnosis may be delayed which may result in major deformity and amputation of the foot (3).
Mechanisms contributing to the pathogenesis of Charcot foot as well as the markers of the disease and methods of early diagnosis remain largely unknown. It is possible that the recently described  cytokines RANKL and OPG may contribute to the pathogenesis of  osteolytic bone disorder seen in this condition (4). The RANK/OPG pathway plays a dominant role in the process of bone formation and osteolysis, and imbalance of RANKL and OPG has been shown to be involved in bone loss and arthritis of various diseases  ADDIN EN.CITE (5, 6).  In the recent publication by Mabilleau et al., the authors have showed RANKL-mediated osteoclastic  resorption in acute Charcot’s osteoarthropathy (7). 




Patients and control group
54 consecutive  patients with Charcot osteoarthropathy (the Ch group; 37 men, 17 women; 12 with type 1, 42 with type 2) and 35 diabetic patients with no history of Charcot osteoarthropathy  (the ND group; 24 men,11 women; 5 with type 1, 30 with type 2), as well as 95 healthy controls (the C group; 47 men and 46 women) were included in the study. In the non-Charcot diabetic group patients were required to have vibration perception threshold (VPT) >25V and normal foot radiographs. The control group included unrelated individuals that worked at a hospital or were hospitalized for reasons other than diabetes, and who have never been diagnosed with diabetes (covering the same geographical area as the case group). All studied patients were Caucasian. The mean duration of diabetes was similar in the group of Charcot patients and in the non-Charcot neuropathic patients (175.7 ± 133.3 and 197.0 ± 111.7, respectively; p=0.36). HbA1c  concentration indicating diabetes control was also similar between the diabetic groups (8.6±1.8% in the Charcot group and 8.1± 1.6% in the non-Charcot neuropathic group; p=0.12). Patients without Charcot arthropathy were significantly older as compared with the Charcot group (61.8 ±7.6 and 53.7 ±9.4 years, respectively; p<0.001).
Charcot’s osteoarthropathy was diagnosed on the basis of clinical presentation of a hot swollen foot and skin foot temperature  more than 2°C higher than the contralateral foot and  confirmed by typical radiological findings (destruction or fracture of bone, joint sublucsation or destruction ) on standard foot radiographs in two projections  ADDIN EN.CITE (10, 11). Neuropathy was diagnosed on clinical grounds after quantitative assessement of vibration perception  (Vibratron II Physitemp Instr.Inc, Clifton NJ), determined as average of three readings.  Threshold above 25V was considered pathological (12). Assessment of pressure sensation (10g Semmes-Weinstein monofilament-Touch-Test Sensory Evaluator;North Coast Medical, Morgan Hill,CA) and qualitative assessment of thermal threshold (TipTherm, Bailey Instruments Ltd) were also performed. In the group of patients with neuropathy Charcot arthropathy was excluded on the basis of a lack of typical clinical presentation and normal radiographs.
This study was approved  by Medical University in Gdańsk Research Ethics Committee and it was conducted in accordance with Helsinki Declaration. All participants gave written informed consent.

DNA extraction
Approximately 5 ml of whole venous blood was collected in EDTA tubes and was kept at -20oC. DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Germany). The extraction protocol as outlined in the manufacturer protocol was followed. 

OPG genotyping analysis
OPG genotyping was performed by a polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) method. Five DNA fragments were amplified from genomic DNA: (i) a 300 bp fragment and containing the 245T>G single nucleotide polymorphism (SNP, rs3134069, 928 bp upstream of the translation initiation site), (ii) a 342 bp fragment containing the 950T>C SNP (rs2073617, 223 bp upstream of the translation initiation site) in the OPG 5' untranslated region, (iii) a 147 bp fragment containing the 1181G>C SNP (rs2073618, located in exon 1), (iv) a 298 bp fragment containing the 1217C>T (rs3102734, in intron 1), and (v) a 381 bp fragment containing the 6890A>C SNP (rs7844539, in intron 4). Numbers of polymorphism are in accordance with Morinaga et al (13). The choice of studied  polymorphisms was based on the report on correlation between osteoprotegerin gene polymorphisms and osteoporosis (8).
PCR amplification of fragments of the OPG gene was performed with oligonucleotide primers (Table 1), and was followed by restriction endonuclease digestion. The PCR products were digested with HinfI, HindII, SmlI, BsuRI or BclI restriction endonuclease to detect the 245T>G, 950T>C, 1181G>C, 1217C>T or 6890A>C polymorphism, respectively. The digestion products were electrophoresed in agarose gels containing 0.5 µg/ml ethidium bromide. The gels were visualized on a transilluminator under ultraviolet light and photographed.
Digestion of the fragment containing 245 T→G with HinfI resulted in either two fragments of 245 and 55 bp (the C allele) or a single 300 bp fragment (the A allele). Digestion of the PCR products containing 950T>C with HindIII resulted in either two fragments of 225 and 117 bp (the C allele) or a single 342 bp fragment (the T allele). The 147-bp PCR product was cleaved by SmlI into 123- and 24-bp fragments only in the presence of a C nucleotide at position 1181, while the presence of G at this nt position resulted in a single 147 bp fragment. In the presence of a C nucleotide at position 1217, the 298 bp PCR product was cleaved by BsuRI into 166 and 132 bp fragments, while it remained intact in the presence of T. Digestion of the PCR product containing 6890A>C by BclI resulted in appearance of two fragments of 296 and 85 bp (the C allele) or a single 381 bp fragment (the A allele).

Statistical analysis




Clinical and laboratory characteristics of patients with diabetic Charcot neuroarthropathy (the Ch group) and subjects with diabetic neuropathy without Charcot neuroarthropathy (N group) is shown in Table 2. Statistically significant differences between these two groups were observed only for age and CRP levels.  
The analysis of frequencies of particular genotypes, based on the OPG gene polymorphism, in subjects from ND, Ch and C (control) groups is presented in Table 3. Statistically significant differences between ND and C groups were found for 1217C>T, 1181G>C, 950T>C and 245T>G polymorphisms, between Ch and C groups for 1217C>T, 1181G>C and 950T>C polymorphisms, and between ND and Ch groups for 1217C>T and 245T>G polymorphisms. No significant differences between any groups were detected for the 6890A>C polymorphism.
Genetic distribution of polymorphisms for the whole tested population was in Hardy-Weinberg equilibrium for most genotypes, except 1217C>T. When each group (ND, Ch or C) was tested separately, the genetic distribution of all polymorphisms was in Hardy-Weinberg equilibrium.




The role of OPG polymorphism has been  recently  sugessted in osteoporosis (8)  and some authors have described contribution of polymorphisms in the promoter region of OPG in the genetic regulation of bone mineral density(14).
Previous report by Pitocco et al. ADDIN EN.CITE (9) described a comparison of two OPG gene polymorphisms, 1181G>C and 245T>G, between Italian groups of diabetic Charcot neuroarthropathy patients, patients with diabetic neuropathy without Charcot neuroarthropathy, and healthy (control) subjects. In that study, significant differences in frequencies of alleles between the two first groups, and between Charcot patients and control subjects were detected, while there were no significant differences between patients with diabetic neuropathy without Charcot neuroarthropathy, and healthy subjects. That was the first, and to our knowledge the only one (to date) report indicating a correlation between diabetic Charcot neuroarthropathy and OPG gene polymorphisms.  
In this study, we analyzed five OPG gene polymorphisms in the Polish population, divided into the same groups: diabetic Charcot neuroarthropathy patients (called Ch in this report), patients with diabetic neuropathy without Charcot neuroarthropathy (ND), and control subjects (C). Results of our studies support the previous conclusion of Pitocco et al.  ADDIN EN.CITE (9) that genetic factors, like OPG gene polymorphisms, play an important role in development of diabetic Charcot neuroarthropathy. However, detailed results of analyses of OPG genotypes indicated correlations that are partially different from those reported previously. Particularly, in the Polish population, frequencies of 1181G>C and 950T>C polymorphisms are not significantly different between Ch and ND groups, while there is a significant difference in frequencies  between the neuropathic patients (Ch or ND) and non-diabetic subjects (C). 
We confirmed a conclusion of Pitocco et al.  ADDIN EN.CITE (9) that there is a statistically significant difference in frequency of particular alleles at residue 245 between Ch and ND groups, and found that a similar correlation occurs also for the 1217C>T polymorphism. In the Polish population, for both 1217C>T and 245T>G, there is a positive correlation between TT genotypes and Charcot neuroarthropathy. Namely, in the group of neuropathic patients, the TT genotype at 1217 or 245 residue results in over 3-times higher probability of occurrence of Charcot foot (OR=3.19 [1.05-9.63], p=0.04 and OR=3.61 [1.21-10.775], p=0.021, respectively). We did not find any other correlations between frequencies of particular tested OPG genotypes and occurrence of Charcot neuroarthropathy among neuropathic patients. We suggest that differences between results presented here and those reported by Pitocco et al.  ADDIN EN.CITE (9) may arise from genetic differences in loci other than OPG between tested populations (Polish and Italian, respectively), as undoubtedly there must be some other genes involved in development of diabetic Charcot neuroarthropathy. 
Regarding other factors that can influence the development of diabetic Charcot neuroarthropathy, on the basis of logistic regression analysis, in which Charcot neuroarthropathy was a depended variance, we found that following factors correlated with occurrence of this diabetic complication: age (OR=0.84 [95% CI 0.77-0.91], p<0.001), the presence of retinopathy (RTP) (OR=3.08 [1.00-9.46], P=0.049), and CRP (OR=1.58 [1.21-2.06], p=0,001).   
Performed analyses indicated that in the tested population: (i) among patients with the TT genotype at the 1217 residue of OPG there is a 8.5-fold higher risk of Charcot neuroarthropathy than among patients with TC or CC genotypes, and (ii) among patients with the TT genotype at the 245 residue of OPG there is a 11.5-fold higher risk of Charcot neuroarthropathy than among patients with TC or CC genotypes. Moreover  the risk of Charcot neuroarthropathy is 3.08 higher in patients with other microvascular complications namely retinopathy (3.08 –fold higher risk) and in those  with the higher values of hsCRP=5 there is a 2.5-fold higher risk of Charcot neuroarthropathy than among patients with hsCRP=3.
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Table 1. Primers, PCR reaction conditions and enzymes used for analysis of PCR products during testing the OPG gene polymorphisms

Polymorphism	Primers (5’-3’)	Annealing temperature 	Product size (bp)	Restriction enzyme	Reference
950T>C	F:GTTCCTCAGCCCGGTGGCTTTT R:TGTGGTCCCCGGAAACCTCAGG	65°C	342	HindIΙ 	Langdahl et al. (8)
245T>G	F:CTGGAGACATATAACTTGAACA R:CCATCATCAAAGGGCTATTGGT 	53°C	300	Hinf Ι	Langdahl et al. (8)
1181G>C	F:ACTTCCTGTYGCCGGGAVCGCTAR:TACCACGAGCGCGCAGCACCTCA	60°C	147	SmlI	Langdahl et al. (8)
6890A>C	F:GTATTGAATAGACTCTCAGAAAR:AACTAAACATACATGCAGTCTT	51°C	381	BclI	Langdahl et al. (8)


































Table 2. Clinical and laboratory characteristics of patients with diabetic Charcot neuroarthropathy (Ch group) and subjects with diabetic neuropathy without Charcot neuroarthropathy (ND group). Data are means ± SD.

Measurement	ND groupmeans ± SD	Ch groupmeans ± SD	p valuea
Age (years)	61.8 (±7.6)	53.7 (±9.4)	p<0.001
Weight (kg)	90.1 (15.4)	91.8 (16.2)	NS
Height (cm)	173.1 (9.4)	173.8 (8.8)	NS
BMI (kg/m2)	30.2 (±5.4)	30.4 (±4.9)	NS
Diabetes duration (months???)	197.0 (±111.7)	175.7 (±133.3)	NS
HBA1c (%) 	8.1 (±1.6)	8.6 (±1.8)	NS
CRP (mg/l)	3.3 (±2.7)	5.0 (±3.0)	p=0.003








Table 3. Frequencies of the genotypes, and statistical analysis of differences between diabetic Charcot neuroarthropathy (Ch), diabetic neuropathy without Charcot (ND) and control (C) subjects.  

Genotypes	ND (%)	Ch (%)	C (%)
6890A>C	ND vs. C: χ2=0.14 p=0.93	Ch vs. C: χ2=1.63, p=0.44	ND vs. Ch χ2=2.03, p=0.36
A/A		33 (73.3%)	58 (81.7)	74 (77.9%)
A/C		10 (22.2%)	13 (18.3%)	19 (20.0%)
C/C		1 (2.2%)	0 (0%)	2 (2.1%)
   1217C>T	ND vs. C: χ2=6.61, p=0,010	Ch vs. C: χ2=0.07, p=0.797	ND vs. Ch χ2=4,62, p=0.032
C/C		0 (0%)	0 (0%)	0 (0%)
C/T		10 (22.2%)	6 (8.5%)	7 (7,4%)
T/T		34 (75.6%)	65 (91.5%)	88 (92,6%)
   1181G>C	ND vs. C: χ2=3.12, p=0.210	Ch vs. C: χ2=7.12, p=0.028	ND vs. Ch χ2=0.39, p=0.82
G/G		6 (13,3%)	9 (12,7%)	23 (24.2%)
G/C		25 (55,6%)	37 (52,1%)	54 (56.8%)
C/C		13 (28,9%)	25 (35,2%)	18 (18.9%)
  950T>C	ND vs. C: χ2=7.35, p=0.025	Ch vs. C: χ2=11.22, p=0.004	ND vs. Ch χ2=1.07, p=0.59
T/T		10 (22.2%)	11 (15.5%)	29 (30.5%)
T/C		18 (40.0%)	34 (47.9%)	51 (53.7%)
C/C		16 (35.6%)	26 (36.6%)	15 (15.8%)
  245T>G	ND vs. C: χ2=8.29, p=0.004	Ch vs. C: χ2=0.066, p=0.80	ND vs. Ch χ2=5.91, p=0.015
AA		33 (73.3%)	65 (91.5%)	88 (92.6%)
AC		11 (24.4%)	6 (8.5%)	7 (7.4%)



























Table 4. Linkage disequilibrium between paired SNP markers at the OPG locus













Data were analyzed for significance by using values from all markers in the study. P
values were 0.000001 except for A (P = 0.216), B (P = 0.831) and C (P = 0.881). D’ is the normalized linkage disequilibrium statistic, which lies in the range {0,1} with greater values indicating stronger linkage disequilibrium. 
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